| Drug General Information |
| Drug ID |
D0M4KE
|
| Former ID |
DNC001093
|
| Drug Name |
Parthenolide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 2 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C15H20O3
|
| Canonical SMILES |
CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C
|
| InChI |
1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13+,15+/m0/s1
|
| InChIKey |
KTEXNACQROZXEV-PVLRGYAZSA-N
|
| CAS Number |
CAS 20554-84-1
|
| PubChem Compound ID |
|
| PubChem Substance ID |
12413771, 24278621, 24671467, 26756789, 26759317, 43064522, 47424978, 47424979, 47574105, 47721336, 47795785, 48244093, 48319197, 49699109, 50973094, 56463706, 57372321, 87246424, 92125565, 92309724, 99300638, 99302156, 103914300, 119503412, 119526028, 121363236, 123124679, 137023626, 140579898, 162187690, 163413395, 163687534, 163849138, 164196500, 175442100, 175607772, 184812409, 210280224, 210282203, 223394255, 223560388, 226399466, 238364679, 241038632, 242082896, 242084666, 249867955, 252068420, 252301908, 252455448
|
| Target and Pathway |
| Target(s) |
Inhibitor of nuclear factor kappa B kinase beta subunit |
Target Info |
Inhibitor |
[2]
|
|---|
| Nuclear factor NF-kappa-B |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Chemokine signaling pathway
|
|
NF-kappa B signaling pathway
|
|
FoxO signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Insulin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
HTLV-I infection
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Prostate cancer
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancerhsa04010:MAPK signaling pathway
|
|
Legionellosis
|
|
Viral carcinogenesis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interleukin signaling pathway
|
|
PDGF signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathwayP00006:Apoptosis signaling pathway
|
|
Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
TCR signaling in naï
|
|
Canonical NF-kappaB pathway
|
|
TRAIL signaling pathway
|
|
TCR signaling in naï
|
|
FAS (CD95) signaling pathway
|
|
IL1-mediated signaling events
|
|
mTOR signaling pathway
|
|
TNF receptor signaling pathway
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
Validated transcriptional targets of TAp63 isoforms
|
|
Endogenous TLR signalingil12_2pathway:IL12-mediated signaling events
|
|
Alternative NF-kappaB pathway
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and AdenosinePW000445:Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
Activation of NF-kappaB in B cells
|
|
NOD1/2 Signaling Pathway
|
|
RIP-mediated NFkB activation via ZBP1
|
|
p75NTR recruits signalling complexes
|
|
NF-kB is activated and signals survival
|
|
FCERI mediated NF-kB activation
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Interleukin-1 signaling
|
|
Regulation of TNFR1 signaling
|
|
TNFR1-induced NFkappaB signaling pathway
|
|
IKBKB deficiency causes SCID
|
|
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
|
IkBA variant leads to EDA-ID
|
|
CLEC7A (Dectin-1) signaling
|
|
MAP3K8 (TPL2)-dependent MAPK1/3 activation
|
|
TRAF6 mediated NF-kB activation
|
|
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
|
|
IRAK1 recruits IKK complex
|
|
IKK complex recruitment mediated by RIP1
|
|
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulationR-HSA-1810476:RIP-mediated NFkB activation via ZBP1
|
|
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
|
|
Interleukin-1 processing
|
|
Dectin-1 mediated noncanonical NF-kB signaling
|
|
NIK-->noncanonical NF-kB signaling
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Estrogen signaling pathway
|
|
TCR Signaling Pathway
|
|
Insulin Signaling
|
|
IL-4 Signaling Pathway
|
|
MAPK Signaling Pathway
|
|
NLR Proteins
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
MyD88 cascade initiated on plasma membrane
|
|
Cardiac Hypertrophic Response
|
|
Cytosolic sensors of pathogen-associated DNA
|
|
MyD88 dependent cascade initiated on endosome
|
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
|
MyD88:Mal cascade initiated on plasma membrane
|
|
Fc epsilon receptor (FCERI) signaling
|
|
MyD88-independent cascade
|
|
Signaling by the B Cell Receptor (BCR)
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
EBV LMP1 signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Apoptosis
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
BDNF signaling pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TNF alpha Signaling Pathway
|
|
B Cell Receptor Signaling Pathway
|
|
IL17 signaling pathway
|
|
TWEAK Signaling Pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Signalling by NGF
|
|
IL-1 signaling pathway
|
|
TCR signaling
|
|
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
|
|
Interleukin-1 signaling
|
|
Apoptosis Modulation and Signaling
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Regulation of toll-like receptor signaling pathway
|
|
Osteopontin Signaling
|
|
NOD pathwayWP75:Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
SIDS Susceptibility Pathways
|
|
Nuclear Receptors Meta-Pathway
|
|
TSLP Signaling Pathway
|
|
Neural Crest Differentiation
|
|
Interleukin-1 processing
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | ClinicalTrials.gov (NCT00133341) Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate. U.S. National Institutes of Health. |
|---|
| REF 2 | The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66. |
|---|
| REF 3 | Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15. |
|---|
